Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that Naresh Tanna, Chief of Staff to the CEO, has been promoted to Vice President of Investor Relations to enhance and expand its IR program and communications with shareholders.

“Since joining Precision BioSciences as my Chief of Staff at the start of 2022, Naresh has had a unique vantage point to Precision’s management team and board of directors with a key role in executing our day-to-day operations and strategy,” said Michael Amoroso, Chief Executive Officer of Precision BioSciences. “Naresh’s breadth of experience before Precision, along with the deep knowledge gained since joining the company, position him to successfully lead communications with our shareholders. He has made important contributions to our investor relations activities starting with Precision’s 2023 In Vivo R&D Day and, we look forward to the impact he will make in this expanded role.”

Naresh assumes leadership of the investor relations function following the promotion of Mei Burris, CPA to Senior Director of Finance and Corporate Controller in September 2023. Naresh will continue to serve as an integral member of the Senior Leadership Team helping to drive Precision’s corporate strategy into fruition as it advances its wholly owned in vivo gene editing programs towards clinic.

Mr. Tanna joined Precision BioSciences in January 2022 as Chief of Staff to the CEO. He brings over 18 years of diverse experiences across Oncology, Infectious Diseases and Rare Diseases across treatment modalities. Mr. Tanna has held roles in global oncology marketing at Amgen and Eli Lilly and global hematology at Abbvie and Celgene, focusing on marketing, strategy and execution across commercial and development stage products. Earlier in his career, he held life sciences consulting roles at Trinity Partners and Clarkston Consulting. Mr. Tanna holds an M.B.A. from the IESE Business School and a B.S. in Biomedical Engineering and Political Science from Rutgers School of Engineering.